← Product Code [JWH](/productcode/JWH) · K140222 # SAIPH KNEE SYSTEM (K140222) _Matortho · JWH · Nov 17, 2014 · Orthopedic · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K140222 ## Device Facts - **Applicant:** Matortho - **Product Code:** [JWH](/productcode/JWH.md) - **Decision Date:** Nov 17, 2014 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3560 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic, Real-World Evidence ## Real-World Evidence | Submission | Device | Sponsor | RWD Sources | RWE Use Summary | Key Tags | | --- | --- | --- | --- | --- | --- | | K140222 · Nov 17, 2014 | SAIPH KNEE SYSTEM | Matortho | UK National Joint Registry; Multi-center post-market clinical study (Australia and UK) | The sponsor provided registry data and post-market clinical study results to demonstrate the safety and effectiveness of the Saiph® Knee System, noting low revision rates and no device-related failures. | National Joint Registry; Post-market clinical study; Revision rates | ### Clinical Evidence | Study Design | Population | Comparator | Key Endpoints | | --- | --- | --- | --- | | National Joint Registry (UK) data; Registry cohort; Follow-up/Duration: 1.6 to 4.8 years | Patients undergoing total knee arthroplasty; Sample Size: 127 procedures | Not applicable for this study | Revision rate | | Multi-center post-market study; Multi-center post-market study; Follow-up/Duration: Average 1.9 years (range 0.6 to 5 years) | Patients receiving Saiph® Knee System implants; Sample Size: 282 implants; Number of Sites: Multi-center (Australia and UK) | Not applicable for this study | Revision rate | ## Indications for Use Cemented total joint replacement intended to replace diseased or severely worn articulating surfaces of the knee joint. ## Device Story Saiph Knee System is a total knee arthroplasty prosthesis replacing articulating surfaces of femur, tibia, and patella. Components include cast cobalt chrome femoral and tibial tray components and UHMWPE tibial bearing and patella. Device is intended for cemented fixation only; components are gamma irradiated. Used in orthopedic surgery by surgeons to treat degenerative joint disease, deformities, or fractures. System includes surgical instrumentation. Device functions as a semi-constrained prosthesis to restore joint function and reduce pain. Clinical benefit derived from successful joint replacement and improved mobility. ## Clinical Evidence Clinical evidence includes data from UK National Joint Registries (127 procedures, 1.6-4.8 years follow-up, 0 revisions) and an ongoing multi-center post-market study in Australia and the UK (282 implants, 0.6-5 years follow-up, 3 revisions, 0 device-related failures). Data validates that surgical instruments meet user needs and the system is safe and effective. ## Technological Characteristics Materials: Cast cobalt chrome (femoral/tibial tray), UHMWPE (tibial bearing/patella). Principle: Semi-constrained cemented knee prosthesis. Connectivity: None. Sterilization: Gamma irradiation. Design features: Stippled cemented surface, barb locking mechanism for tibial tray/bearing. ## Regulatory Identification A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027). ## Predicate Devices - Medial Rotation Knee (MRK) System ([K020214](/device/K020214.md)) - NexGen Complete Knee Solution Cruciate Retaining (CR)-Flex Femoral Components ([K023211](/device/K023211.md)) - NexGen Complete Knee Solution Crosslinked Polyethylene Cruciate Retaining (CR) Articular Surface Components ([K003910](/device/K003910.md)) - NexGen Complete Knee Solution ([K963148](/device/K963148.md)) - Triathlon PS Knee ([K031729](/device/K031729.md)) - Insall Burstein II ([K935080](/device/K935080.md)) - PFC Modular Total Knee System ([K931466](/device/K931466.md)) - Duracon Constrained PS Knee ([K932070](/device/K932070.md)) - Genesis PS Knee ([K946088](/device/K946088.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. The profiles are black against a white background. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 November 17, 2014 MatOrtho Limited % Mr. Marcos Velez-Duran President M-Squared Associates Incorporated 815 King Street Alexandria, Virginia 22314 Re: K140222 Trade/Device Name: Saiph® Knee System Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis Regulatory Class: Class II Product Code: JWH Dated: October 9, 2014 Received: October 14, 2014 Dear Mr. Velez-Duran: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing {1}------------------------------------------------ ### Page 2 - Mr. Marcos Velez-Duran (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, # Lori A. Wiggins -S for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ #### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration # Indications for Use 510(k) Number (if known) K140222 Device Name Saiph® Knee System Indications for Use (Describe) The Saiph® Knee System is intended for cemented only in the U.S. It is intended for single use in total knee arthroplasty surgery for the reduction or relief of paintined only in the U.S. It is intended to single use in total knear patients with the following - 1. Non-inflammatory degenerative joint disease resulting from osteoarthritis and avascular necrosis; - 2. Inflammatory degenerative joint disease including rheumatoid arthritis; - 3. Correction of varus, valgus, or post traumatic deformity; - 4. Correction or revision of unsuccessful osteotomy or arthrodesis; - 5. Revision procedures where other treatments or devices have faily and 6. Treatment of fractures that are unmanageable using other techniques. Type of Use (Select one or both, as applicable) > Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) # CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. # *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review ins believing in information is estimated to average 79 hours per response, including the and review instructions, search existing data sources, gather and ma and review the collection of information. Send comments the data needed and complete of this information. Send comments regraing this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of the information unless it displays a currently valid OMB number." {3}------------------------------------------------ | Submitter Information | | |------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Name | MatOrtho Limited | | Address | 13 Mole Business Park
Randalls Road
Leatherhead
Surrey
KT22 7BA
United Kingdom | | Phone number | +44 (0)1372 224 200 | | Fax number | +44 (0)1372 366 343 | | Establishment Registration
Number | 9035148 | | Name of contact person | Marcos Velez-Duran | | Date prepared | October 8, 2014 | | Name of device | | | Trade or proprietary name | Saiph® Knee System | | Common or usual name | Knee Prosthesis | | Classification name | Knee joint patellofemorotibial polymer/metal/polymer semi-
constrained cemented prosthesis (Class II) | | Classification panel | Orthopedic | | Regulation | 21 CFR 888.3560 | | Product Code(s) | 87JWH | | Legally marketed device(s)
to which equivalence is
claimed | K020214 - Medial Rotation Knee™ (MRK) System (JWH)
K023211 - NexGen® Complete Knee Solution Cruciate
Retaining (CR)-Flex Femoral Components (JWH)
K003910 - NexGen® Complete Knee Solution Crosslinked
Polyethylene Cruciate Retaining (CR) Articular
Surface Components (JWH)
K963148 - NexGen® Complete Knee Solution (JWH)
K031729 - Triathlon® PS Knee (JWH)
K935080 - Insall Burstein II
K931466 - PFC Modular Total Knee System | | | K932070 - Duracon® Constrained PS Knee | | Reason for 510(k)
submission | New device | | Device description | The Saiph® Knee System is used in total knee replacement to
replace articulating surfaces of the femur, tibia and patella.
The device is intended for cemented fixation only. The patella
is optional depending upon surgeon preference and is
cemented use only. The femoral and tibial tray components
are made from cast cobalt chrome. The tibial bearing and
patella components are made from ultra-high molecular
weight polyethylene (UHMWPE). The femoral component is
highly polished to articulate with the tibial bearing. All
devices are gamma irradiated. | | Intended use of the device | Cemented total joint replacement intended to replace diseased
or severely worn articulating surfaces of the knee joint. | | Indications for use | The Saiph® Knee System is intended for cemented only in the
U.S. It is intended for single use in total knee arthroplasty
surgery for the reduction or relief of pain and/or improved knee
function in skeletally mature patients with the following
conditions:

1. Non-inflammatory degenerative joint disease
resulting from osteoarthritis, traumatic arthritis and
avascular necrosis;

2. Inflammatory degenerative joint disease including
rheumatoid arthritis;

3. Correction of varus, valgus, or post traumatic
deformity;

4. Correction or revision of unsuccessful osteotomy or
arthrodesis;

5. Revision procedures where other treatments or
devices have failed; and

6. Treatment of fractures that are unmanageable using
other techniques. | K946088 - Genesis® PS Knee # 510(k) Summary {4}------------------------------------------------ {5}------------------------------------------------ ## Summary of the technologies The Saiph® Knee System is comprised of the multiple components including femorals, tibial trays and bearings, and patella, as well as instrumentation. The technological characteristics are the same as the predicate devices (K020214, K023211, K003910. K963148 and K031729) in terms of design. materials, and principle of operation with the exception of the slight modifications outlined in this 510(k) submission. The femur, tibia and patellar components utilize the identical manufacturing processes as the predicate, Medial Rotation Knee™ (MRK) System (K020214). This includes the same cemented (stippled) surface and "barb" locking mechanism used for the tibial tray and tibial bearing. Non-clinical tests were used to characterize the physical aspects of the design and to demonstrate substantial equivalence to the predicate devices. A summary of physical testing is given in the Performance Data (Non-clinical) section below. Physical testing is considered acceptable and equivalent to predicate devices. Clinical evidence of the Saiph is available in Australia and Europe and the device has been in use since 2009. A summary of Clinical Data is given below. # PERFORMANCE DATA # SUMMARY OF NON-CLINICAL TESTS ## Performance Test Summarv-New Device The Saiph® Knee System has been evaluated for tibial tray fatigue strength, insert locking mechanism strength, tibiofemoral range of motion, tibiofemoral range of constraint, patellofemoral range of constraint, tibiofemoral contact stress and patellofemoral contact area and contact stress. The testing confirms that the Saiph® Knee System is capable of withstanding loads in excess of those expected in vivo and is substantially equivalent to the competitive legally marketed knee systems. # SUMMARY OF CLINICAL TESTS Clinical usage in Europe (England and Belgium) and Australia validated that the specific surgical instruments included with this system meet user needs. A total of 127 procedures have been registered by the National Joint Registries in the UK. Maximum follow up is 4.8 years (minimum 1.6 years). There have been no reports of revisions. A multi-center, post-market study is ongoing in the Australia and the UK with 282 implants. The implants have been followed for average 1.9 years (range 0.6 to 5 years). There have been 3 revisions. {6}------------------------------------------------ There have been no device related failures. # CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA The Saiph® Knee System was found to be substantially equivalent to the predicate devices based on non-clinical testing. Clinical data from the National Joint Registry in the UK and data from a post-market clinical study being conducted in Australia and the UK show that the Saiph® Knee System is safe and effective. There have been no device related failures. --- **Source:** [https://fda-staging.innolitics.com/device/K140222](https://fda-staging.innolitics.com/device/K140222) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com